
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is a promising company with a strong partnership portfolio in the biopharma industry, which is expected to generate consistent and recurring revenue. With a focus on expanding its customer base, SOPH aims to reach breakeven by 2026 and become profitable by 2027. Their innovative use of AI technology and recent partnerships and offerings are projected to drive growth and have led to a favorable price target increase by analysts.
Bears say
Sophia Genetics is not yet a profitable company, and its potential for future profitability is uncertain despite its strong growth potential in the healthcare technology sector. Additionally, competition in the precision oncology diagnostics market and the need for further investments in product development may hinder its profitability in the near term. Furthermore, the company's valuation appears to be on the lower end compared to historical averages in the sector, possibly due to it being a data software business with high gross margins.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares